Hikma core operating profit jumps on higher sales of injectable drugs

The Jordan-based drugmaker said its core operating profit rose to $460 million for the year ended December 31. (Reuters)
Updated 13 March 2019
0

Hikma core operating profit jumps on higher sales of injectable drugs

  • The Jordan-based drugmaker said its core operating profit rose to $460 million for the year ended December 31
  • Core revenue rose 7 percent to $2.08 billion

BENGALURU: Hikma Pharmaceuticals on Wednesday reported a 19 percent rise in full-year core operating profit, helped by strong demand for its injectable drugs and a rebound in its generics business.
The Jordan-based drugmaker said its core operating profit rose to $460 million for the year ended Dec. 31 from $386 million a year earlier.
Core revenue rose 7 percent to $2.08 billion, with Hikma’s injectables business accounting for about 40 percent of the total.


Owner of Abu Dhabi’s Al Hilal Bank appoints chairman and CEO

Updated 21 April 2019
0

Owner of Abu Dhabi’s Al Hilal Bank appoints chairman and CEO

  • Eraiqat is currently group chief executive of Abu Dhabi Commercial Bank (ADCB)
  • Eraiqat will serve as chairman at Al Hilal in addition to his current role at ADCB

DUBAI: Abu Dhabi Islamic lender Al Hilal Bank said on Sunday its owner, the Abu Dhabi Investment Council, had appointed Alaa Eraiqat as the bank's chairman.
Eraiqat is currently group chief executive of Abu Dhabi Commercial Bank (ADCB), which is expected to merge with Al Hilal Bank and Union National Bank (UNB) in the first half of 2019.
Eraiqat will serve as chairman at Al Hilal in addition to his current role at ADCB.
The Abu Dhabi Investment Council, a sovereign wealth fund which combined with Abu Dhabi state fund Mubadala last year, also appointed Amr Saad Al Menhali as chief executive of Al Hilal Bank.